Insider Selling: Moderna, Inc. (NASDAQ:MRNA) Insider Sells 162 Shares of Stock

Moderna, Inc. (NASDAQ:MRNA) insider Shannon Thyme Klinger sold 162 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $78.03, for a total transaction of $12,640.86. Following the sale, the insider now directly owns 17,447 shares in the company, valued at approximately $1,361,389.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shannon Thyme Klinger also recently made the following trade(s):

• On Monday, June 10th, Shannon Thyme Klinger sold 5,178 shares of Moderna stock. The shares were sold at an average price of $148.09, for a total transaction of $766,810.02.

Moderna Stock Down 0.2 %

Moderna stock traded down $0.19 during midday trading on Friday, hitting $77.40. 3,585,187 shares of the stock were exchanged, compared to its average volume of 4,083,584. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.09 and a quick ratio of 3.91. The company has a 50 day moving average price of $105.74 and a two-hundred day moving average price of $112.88. The firm has a market cap of $29.66 billion, a P/E ratio of -4.94 and a beta of 1.67. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same quarter last year, the firm earned ($3.62) EPS. Moderna’s quarterly revenue was down 29.9% on a year-over-year basis. On average, sell-side analysts predict that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Quadrant Capital Group LLC raised its stake in shares of Moderna by 7.5% in the 4th quarter. Quadrant Capital Group LLC now owns 2,672 shares of the company’s stock valued at $266,000 after purchasing an additional 187 shares in the last quarter. Ontario Teachers Pension Plan Board bought a new stake in Moderna in the fourth quarter valued at about $1,358,000. Hobbs Group Advisors LLC acquired a new stake in Moderna during the fourth quarter valued at approximately $664,000. Illinois Municipal Retirement Fund lifted its holdings in Moderna by 22.1% during the 1st quarter. Illinois Municipal Retirement Fund now owns 51,791 shares of the company’s stock worth $5,519,000 after buying an additional 9,360 shares during the last quarter. Finally, Swedbank AB acquired a new position in shares of Moderna in the 1st quarter worth approximately $3,315,000. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of research reports. The Goldman Sachs Group dropped their price target on Moderna from $204.00 to $178.00 and set a “buy” rating on the stock in a research note on Friday, August 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Thursday, August 1st. William Blair reaffirmed a “market perform” rating on shares of Moderna in a report on Thursday, June 27th. UBS Group upped their price target on shares of Moderna from $143.00 to $151.00 and gave the company a “buy” rating in a report on Tuesday, May 7th. Finally, Canaccord Genuity Group raised their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research report on Friday, May 3rd. Ten research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $123.79.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.